[New protocols for myeloma chemotherapy plus IFN alpha]

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
• Existing treatment regimens for multiple myeloma have limitations in efficacy and toxicity.
• Novel therapeutic strategies are needed to improve outcomes for multiple myeloma patients.

Purpose of the Study:

• To assess the efficacy and toxicity of the combination chemotherapy (CMVM) regimen plus interferon alpha in patients with multiple myeloma.
• To evaluate complete remission (CR) and overall response rates (CR plus partial remission - PR) in two distinct study settings (pilot and multicenter).

Main Methods:

• Two consecutive studies were conducted: a pilot study with 16 patients and a multicenter trial with 61 patients.
• All patients received the CMVM regimen (intermittent high-dose dexamethasone, MCNU, melphalan) combined with interferon alpha (IFN alpha).
• The treatment involved 3 cycles repeated every 6-8 weeks, with a variation in IFN alpha administration duration between studies.

Main Results:

• Complete remission (CR) was achieved in 37.5% of patients in the pilot study and 26.2% in the multicenter trial.
• The overall response rate (CR + PR) was 68.8% in the pilot study and 68.9% in the multicenter trial.
• The CMVM regimen combined with IFN alpha demonstrated a notable efficacy in inducing remission in multiple myeloma.

Conclusions:

• The combination chemotherapy (CMVM) regimen plus interferon alpha shows significant potential as an effective treatment for multiple myeloma.
• The high proportion of complete remissions achieved suggests this protocol may represent a meaningful advance in myeloma therapy.
• Further investigation into the toxicity profile and long-term outcomes is warranted.